Back to News
Market Impact: 0.2
Cerenome Expands CNSide Coverage Through Blue Cross Blue Shield Michigan Deal; Stock Up
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
CNSide Diagnostics, a wholly owned Cerenome subsidiary, signed an in-network provider agreement with Blue Cross Blue Shield of Michigan effective September 1, 2026. The agreement expands insurance-network access for the CNSide cerebrospinal-fluid diagnostic offering and could support patient adoption, though no financial terms or revenue impact were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
CNSY0.55
More News
- Elon Musk once said the Cybertruck would be Tesla’s ‘best product ever.’ Now he’s winding down production
- The AI ‘credit card’ is getting costlier as CoreWeave bond yield tops 16%
- OpenAI to press ahead with data-center expansion despite midterm sweep, CFO tells CNBC
- Elanco Shares Jump After Q3 Beat and Outlook Raise
- FIGS Beats Earnings as Demand Outstrips Supply, CEO Trina Spear Says
- SoftBank, ABB consider China carve-out to rescue $5.4bn robotics deal